crysvita
kyowa kirin holdings b.v. - burosumabs - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - zāles kaulu slimību ārstēšanai - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
artizia 75 mikrogramu/20 mikrogramu apvalkotās tabletes
zentiva, k.s., czech republic - gestodenum, ethinylestradiolum - apvalkotā tablete - 75 μg/20 μg
glucophage 500 mg apvalkotās tabletes
merck sante s.a.s., france - metformīna hidrohlorīds - apvalkotā tablete - 500 mg
leverette 0,15 mg/0,03 mg apvalkotās tabletes
exeltis baltics uab, lithuania - levonorgestrelum, ethinylestradiolum - apvalkotā tablete - 0,15 mg/0,03 mg
valsacombi 80 mg/12,5 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotā tablete - 80 mg/12,5 mg
valsacombi 160 mg/25 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotā tablete - 160 mg/25 mg
valsartan/hydrochlorothiazide krka 160 mg/25 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotās tabletes - 160 mg/25 mg
valsartan/hydrochlorothiazide krka 80 mg/12,5 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotās tabletes - 80 mg/12,5 mg
valsartan/hydrochlorothiazide krka 160 mg/12,5 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotās tabletes - 160 mg/12,5 mg
destele 150/30 mikrogrami tabletes
teva pharma b.v., netherlands - desogestrelum, ethinylestradiolum - tabletes - 150 µg/30 µg